The optimum treatment conditions of interferon (IFN) a therapy in chronic myeloid leukemia (CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN therapy, we conducted a randomized trial to compare the combination of IFN and HU vs HU monotherapy (CML-study II). From February 1991 to December 1994, 376 patients with newly diagnosed CML in chronic phase were randomized. In all, 340 patients were Ph/BCR-ABL positive and evaluable. Randomization was unbalanced 1:2 in favor of the combination therapy, since study conditions were identical to the previous CMLstudy I and it had been planned in advance to add the HU patients of study I (n ¼ 194) to the HU control group. Therefore, a total of 534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU). Analyses were according to intention-to-treat. Median observation time of nontransplanted living patients was 7.6 years (7.9 years for IFN/HU and 7.3 years for HU). The risk profile (new CML score) was available for 532 patients: 200 patients (38%) were low, 239 patients (45%) intermediate, and 93 patients (17%) high risk. Complete hematologic response rates were higher in IFN/HU-treated patients (59 vs 32%). Of 169 evaluable IFN/HU-treated patients (75%), 104 patients (62%) achieved a cytogenetic response that was complete in 12% (n ¼ 21), major in 14% (n ¼ 24), and at least minimal in 35% (n ¼ 59). Of the 534 patients, 105 (20%) underwent allogeneic stem cell transplantation in first chronic phase. In the low-risk group, 65 of 200 patients were transplanted (33%), 30 (13%) in the intermediate-risk group, and nine (10%) in the high-risk group. Duration of chronic phase was 55 months for IFN/HU and 41 months for HU (Po0.0001). Median survival was 64 months for IFN/HU and 53 months for HU-treated patients (P ¼ 0.0063). We conclude that IFN in combination with HU achieves a significant long-term survival advantage over HU monotherapy. In view of the data of CML-study I, these results suggest that IFN/HU is also superior to IFN alone. HU should be combined with IFN in IFN-based therapies and for comparisons with new therapies.
Introduction
In view of the favorable results with interferon a (IFN) and hydroxyurea (HU) therapy in patients with chronic myeloid leukemia (CML) in chronic phase, 1-7 establishment of optimum treatment conditions is important. This is relevant for patient management and for the comparison of outcomes of current IFN-based standard therapy with evolving new therapies such as imatinib, which shows superior hematologic and cytogenetic response rates but still lacks long-term data on survival and toxicity. [8] [9] [10] Optimum conditions of IFN therapy are controversial and may require combination with HU.
In 1991, the German CML Study Group therefore started the randomized comparison of the combination of IFN and HU vs HU alone (CML-study II). Goals of CML-study II were the analyses of whether IFN therapy in combination with HU prolonged duration of chronic phase and survival. 11 Additional goals were the determinations of response rates, adverse drug effects, drug dosages, of whether the terminal phases of the disease differed between the two treatment groups and of whether transplantation outcome was influenced by pretreatments. 12 In comparison with IFN, HU offered a number of advantages such as easy administration, rapid action, efficacy also in advanced phase and prolongation of survival over busulfan at little toxicity. 4, 5, 13 It therefore was common practice to start CML therapy with HU in order to reduce white blood cells (WBC) counts and symptoms rapidly and to use HU as an adjunct to IFN therapy. However, no controlled study on the combination of IFN and HU had been published. As a prelude to CML-study II, the tolerability of the combination of IFN and HU was analyzed in a phase I/II pilot study. 14 The present study establishes, by randomized comparison, that the combination of IFN and HU prolongs duration of the chronic phase and survival in comparison to HU alone. It suggests that the combination is also superior to IFN alone.
Patients and methods

Study protocol
The study outline is shown in Figure 1 . Inclusion criteria were newly diagnosed CML in chronic phase, no prior therapy, and treatment requirement as defined by the presence of at least one of the following criteria: unexplained fatigability, weight loss of more than 10% body weight in 6 months, fever exceeding 38.51C on five consecutive days, organomegaly-related symptoms, WBC count of more than 50 Â 10 9 /l or platelet count of more than 1 Â 10 12 /l at the time of recruitment. Treatment requirement as an entry criterium was also defined to synchronize patients according to stage of disease and thus to have a uniform start to treatment. This criterion reduces a bias in favor of very early CML cases that would be expected to have a particularly long survival.
Patients were randomized between HU monotherapy and IFN/ HU combination therapy. Randomization was 1:2 in favor of the combination therapy, since this arm was more interesting and since patients with HU monotherapy were available for coevaluation from CML-study I (identical inclusion and management criteria). Median time from diagnosis to randomization was 6 days.
No age limit was set. According to the study protocol, cytogenetic results were not required for randomization. Ph-and BCR-ABL-negative patients or patients with unknown BCR-ABL status were excluded later and analyzed separately. Chronic phase (CP) was defined as the absence of any evidence of acceleration as described previously. 2 Blast crisis (BC) was diagnosed if blasts and promyelocytes were more than 30% of peripheral WBC or more than 50% of nucleated cells in the bone marrow or if extramedullary blastic infiltrations were present. Accelerated phase (AP) was diagnosed if the criteria of CP and BC are not anymore, or not yet, respectively, fulfilled.
Patients
A total of 427 patients were recruited from 1 February 1991 until 31 December 1994, representing about 10% of the estimated number of CML cases in Germany over a 4-year period. In all, 51 patients were not randomized because they fulfilled exclusion criteria (mainly no consent (n ¼ 19), no treatment requirement (n ¼ 10), pretreatment (n ¼ 9), no chronic phase (n ¼ 4), or second neoplasias (n ¼ 4)). A total of 376 patients were centrally randomized. In 10 patients (eight randomized to HU, two to IFN/HU), diagnosis of CML was rejected by the central review committee (osteomyelofibrosis in four patients, acute myeloid leukemia in two patients, chronic myelomonocytic leukemia in two patients, unclassified chronic myeloproliferative disorder in one patient, reactive leukocytosis in one patient). In all, 22 patients were Ph-and/or BCR-ABL negative. In four patients, the Ph/BCR-ABL status remained unknown. Of the 340 Ph-and/or BCR-ABL-positive patients, 226 were randomized for the combination of IFNa and HU and 114 for HU monotherapy. Of the 340 eligible patients, 105 (24%) were transplanted in first chronic phase (CML-study I: 15%) and censored at the time of transplantation. However, the extension of the final follow-up time to 7.6 years and the consideration of the HU patients of CML-study I lifted the power of above sample size estimation from under 80 to over 90%. In accordance with the theoretical maximum observation time of CML-study II (11 years, February 1991 to the time of data file closing), the survival time of all HU patients of CML-study I (n ¼ 194) was censored 11 years after the first randomization (July 1983). The HU patients of the two studies did not significantly differ regarding risk profile, 15 HU dosage, censoring patterns, and survival ( Figure 2 ). After comparability of the HU-treatment groups had been ascertained, the two groups were combined for further analysis yielding 308 patients randomized for HU monotherapy.
Diagnostic investigations
Pretherapeutic diagnostic evaluation consisted of history, physical examination (spleen size, extramedullary manifestations, 
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Figure 2
Comparison of survival of HU-treated patients from studies I and II.
Interferon a and hydroxyurea vs hydroxyurea alone R Hehlmann et al weight), complete blood cell count including reticulocytes, alkaline leukocyte phosphatase, serum lactate dehydrogenase (LDH), liver enzymes, creatinine, electrolytes, urinalysis, ECG, cytogenetics, molecular analysis, and bone marrow cytology and histology. Review panels controlled the diagnoses and the quality of bone marrow cytology and histology and of cytogenetic analyses. Investigations at 6 months intervals included inquiry about symptoms (fever, fatigability, adverse effects of drugs), physical examination (weight, search for manifestations of adverse drug effects), complete blood cell count including reticulocytes and LDH, and the determination of drug dosages, liver enzymes, creatinine, electrolytes, urine analysis and ECG.
Additional investigations at 3 months intervals included cytogenetics in the IFN combination arm and screening for IFN antibodies.
Investigations at 12 months intervals included cytogenetics in the HU monotherapy arm and bone marrow cytology and histology.
Documentation was required upon randomization and every 3-6 months. In addition, three checkpoints ( Figure 1 ) were documented: end of chronic phase, beginning of blast crisis, and death.
Therapy
Drug dosages were: IFN 5 Â 10 6 IU/m 2 /day, adapted to 2000-4000 WBC/ml and tolerability; HU 40 mg/kg/day adapted to normal WBC counts (5-15 Â 10 9 /l). In the IFN/HU arm, IFN dose was kept constant as much as possible and HU was added as required. The IFN dosage was reduced in the event of intolerable adverse effects and increased if no therapeutic effect was observed. In this study, IFNa2a (Roferon, Hoffmann-La Roche, Grenzach-Wyhlen, Germany) was used. HU was given continuously and whenever required.
Hematologic remission
Complete hematologic remission was defined by normal WBC count (o10 Â 10 9 /l) with normal differential, normal platelet count (140-450 Â 10 9 /l), normal spleen size, and disappearance of all symptoms. All criteria must be fulfilled. A partial hematologic remission was defined by reduction of WBC count by at least 50% or to less than 20 Â 10 9 /l or by reduction of platelet count and spleen size by at least 50% or by normal CBC with persisting splenomegaly. One criterium suffices. Treatment failure: Criteria of partial remission not fulfilled.
Cytogenetics
For follow-up analyses, 25 metaphases were analyzed whenever possible. For evaluation of cytogenetic response, analyses with less than 10 metaphases were discarded. Complete cytogenetic remission was defined as the absence of any Ph-positive metaphases. Partial cytogenetic remission was defined as 1-34%, a minor cytogenetic response as 35-65%, and a minimal response as 66-95% Ph positivity. For categorization of responders, the best response ever has been used. In 25% of patients, no cytogenetic follow-up analyses were possible mostly due to refusal by patients to have bone marrow punctures performed without recognizable benefit for treatment decisions.
Molecular analyses
The BCR-ABL status was determined by Southern blot analysis 16 and by reverse transcriptase polymerase chain reaction (RT-PCR) techniques according to published procedures. 17, 18 Biostatistics Assuming a ¼ 0.05 (two-sided), b ¼ 0.20, an unbalanced randomization of 1:2, and an accrual and follow-up period of 4 years each, the sample size for CML-study II was estimated in order to be able to detect a 50% superiority in median survival time. 19 Survival time was calculated from date of randomization to date of death or last follow-up. The survival time of patients with stem cell transplantation in first chronic phase was censored at the day of transplantation. Patients who were transplanted in accelerated or blastic phase were not censored at the time of transplantation. To account for the growing number of censorings due to stem cell transplantation, the preplanned inclusion of the HU patients of CML-study I was also to overcome possible power problems.
The primary end point survival time was tested following the group sequential design of O'Brien and Fleming 20 for three analyses with an overall a ¼ 0.05. The two interim analyses (a 1 ¼ 0.00052 and a 2 ¼ 0.01411) were to discover an early statistical superiority leading to a stop of the trial but otherwise still leaving a 3 ¼ 0.04507 close to the overall value for the final analysis. The analyses followed the intention-to-treat strategy. Survival time was compared by Kaplan-Meier estimation and log-rank test. 21 To correct for the time-to-response bias in the comparisons between hematologic and cytogenetic responders and nonresponders, the Mantel-Byar test was applied 22 and survival probabilities were presented by the Simon-Makuch method. 23 All analyses were performed with the program package SAS.
Ethics
The protocol followed the Declaration of Helsinki and was approved by the ethics committee of the Fakultät fü r Klinische Medizin Mannheim of the University Heidelberg and by local ethics committees. Informed consent was obtained from all patients.
Results
Patients' characteristics
In total, 534 patients were available for analysis, 226 patients randomized to receive IFN/HU and 308 to receive HU monotherapy. The initial patients' characteristics are shown in Table 1 . All features were distributed evenly between the two groups except spleen size and organomegaly-related symptoms. Only spleen size as covariate of the new CML score influences survival, but its observed differences had no relevant effect on the survival times of the two treatment arms. Risk profile at diagnosis was available for 532 patients: 200 patients (38%) were low, 239 patients (45%) intermediate, and 93 patients (17%) high risk. In the low-risk group, 65 of 200 patients were transplanted in first chronic phase and censored (33%), 30 of 234 (13%) in the intermediate-risk group, and nine of 93 (10%) in the high-risk group. 15 In one transplanted patient the risk profile could not be determined.
Hematologic and cytogenetic responses
The response rates to the two therapies are depicted in Table 2 . The combination of IFN and HU had superior rates for both complete hematologic remissions (59 vs 32%) and for cytogenetic responses (46 vs 8%). A major cytogenetic response was observed in 45 (20%) patients treated with the combination therapy that was complete in 21 patients (9%) and partial in 24 patients (11%), and in only four (1.3%) patients treated with HU alone. Median time to complete hematologic remission was 238 days in the IFN/HU arm and 364 days in the HU arm (Figure 3a) . Median time to first cytogenetic remission (complete or partial) was 544 days, or 18 months, with first cytogenetic remissions observed up to 76 months after start of IFN therapy (Figure 3b ). Complete hematologic responders have a survival advantage in both treatment groups (Figure 4a and b) . A just nonsignificant (P ¼ 0.0873) survival advantage of cytogenetic responders is observed starting in year 5 after diagnosis (Figure 4c ).
Adverse effects
The adverse effects observed in the two treatment arms are shown in Table 3 . The number of adverse effects is about three times higher in the combination arm. Most adverse effects were not severe, none was life threatening. Of all IFN-treated patients, 24.3% discontinued treatment due to IFN intolerance, 5.3% due to IFN resistance, and 25.7% due to transplantation in first chronic phase (Table 4) . Of the patients, 7.5% did not receive IFN at all, or received IFN for a short period only due to costs, and represented protocol violations. At the time of evaluation, 23 patients representing 13.6% of the 169 IFN/HU-treated patients at risk ( ¼ no transplantation in first chronic phase) still received IFN treatment according to protocol.
Drug dosages and disease control
The median IFN dose applied decreased slowly during the course of treatment from a median of 4.1 Mio U/m 2 at 3 months to a median of about 2 Mio U/m 2 IFN after 8 years (Figure 5a ), whereas the median HU doses remained rather constant in both treatment arms (Figure 5a and b) . WBC counts, as a measure of disease control, were, over the years, according to treatment targets similarly well controlled in both treatment arms as shown in Figure 6 . This group comprises the 194 patients randomized to HU in CML-study I and the 114 patients randomized to HU in CML-study II after comparability of the two groups had been ascertained, see Patients and materials. . The median observation time of these patients was 7.6 years (7.9 years for IFN/HU and 7.3 years for HU-treated patients). The duration of chronic phase ( Figure 7 ) was significantly longer in the IFN/HU combination arm than in the HU monotherapy arm (55 vs 41 months, Po0.0001).
Whereas interim analyses did not show a significant survival difference with regard to the corresponding a-values, the final analysis showed that the IFN/HU combination arm was superior ( Figure 8 ). Median survival time was 64 months for IFN/HU-treated and 53 months for HU-treated patients (P ¼ 0.0063).
Causes of death
The causes of death are summarized in Table 5 . The leading cause of death was blast crisis and related conditions such as infections and hemorrhage in both groups followed by bone marrow aplasia and fibrosis. Bleeding complications may have been less frequent in the IFN/HU combination arm.
Discussion
Based on randomized comparison, the data reported in this paper demonstrate that the combination of IFN and HU is superior to HU monotherapy by response rates, duration of chronic phase and survival. The data further suggest that the combination of IFN and HU is superior also to IFN alone, since IFN monotherapy, in an intention-to-treat analysis of a previous study of our group, did not reach superiority over HU 2 and since all randomized studies showing superiority of IFN over HU used 
Figure 4
Survival of responders vs nonresponders of: (a) IFN/HUtreated patients achieving a complete hematologic remission, (b) HUtreated patients achieving a complete hematologic remission, and (c) IFN/HU-treated patients achieving a partial or complete cytogenetic remission. In (c) never assessed patients are included with the nonresponders. Graphical presentations are according to Simon and Makuch. 23 IFN in combination with HU or other agents when deemed necessary. 1, 5 Optimum IFN treatment, therefore, should include HU.
This outcome is in line with the following theoretical considerations: (1) HU and IFN have different modes of action, which in part may be additive; (2) whereas IFN induces cytogenetic remissions more frequently, reduction of tumor load is more rapid with HU; and (3) complete hematologic remissions are induced more frequently and more rapidly by the combination than by either agent alone, which should translate into a survival advantage. Indeed, combination of IFN with arabinosylcytosine (Ara-C), another cytostatic agent with efficacy in CML, also improves response rates [24] [25] [26] and may prolong survival. In addition, by reducing tumor load rapidly with HU, the patients' symptoms are also quickly relieved. This improves compliance to adhere to an IFN-containing regimen that may also contribute to a prolongation of survival.
With the median observation time of the 102 nontransplanted living patients exceeding median survival time, only slight changes in the observed differences in median duration of chronic phase and survival, if at all, are to be expected in future updates. The fact that another study with similar design did not find a survival difference 27 could be attributed to the smaller sample size and/or the lower IFN dosage used in that study.
The complete hematologic remission rate is higher with the IFN/HU combination than with IFN monotherapy in CML-study I and compares well with the response rates reported in the literature (Table 6 2,7,24,26-28 ). Achieving a complete hematologic remission within 18 months is a prognostic factor in both treatment groups and predicts better survival.
Median time to cytogenetic remission is 18 months similar to that in other reports. 29 First cytogenetic remissions have been observed as late as 76 months after start of IFN therapy (Figure 3b ) in agreement with observations by others. 7 The rate of cytogenetic remissions of 20% in this study compares well with most other randomized IFN studies (Table 6 ). Since the survival advantage of cytogenetic responders is less marked and occurs later than in other studies, this might indicate that cytogenetic responses achieved by additional HU do not possess the same prognostic significance for survival as those induced by IFN alone. Alternatively, it has to be considered that cytogenetic response may not be a good marker for survival in some patients as has been shown for high-risk patients. 30 Adverse effects are higher in the combination arm. In all, 24.3% discontinued IFN due to adverse effects. The majority of patients, however, tolerated IFN reasonably well, and after about 8 years 23 patients (13.6% of nontransplanted IFN/HUtreated patients) still received IFN according to protocol indicating good IFN tolerability at least in a subset of CML patients.
In view of the superior survival outcome and the good tolerability of the IFN/HU combination, the question arises whether the combination of IFN with HU is preferable to the combination of IFN with low-dose araC. Several randomized Never received IFN (n=16) or IFN discontinued because of costs (n=1). c Colitis (n=1), myocardial infarction (n=1), cardiomyopathy (n=1), Raynauds syndrome (n=1), arthritis (n=1), bone marrow fibrosis (n=1), drug addiction (n=1), refusal (n=3), imatinib therapy (n=1). Interferon a and hydroxyurea vs hydroxyurea alone R Hehlmann et al studies find superior response rates of the IFN/araC combination [24] [25] [26] and one study even a survival advantage, 24 but the toxicity of araC is considerable, interfering severely with quality of life and with compliance with treament protocols. 9, 24 One has to keep these considerations in mind in the case that longterm outcomes with imatinib or other new promising drugs are less favorable than currently anticipated.
Causes of death do not differ much between the two therapies, although the death rate due to blast crisis, after a median of 7.6 years is still somewhat lower in the IFN combination arm.
Drug dosages were aimed to keep WBC counts at 2000-4000/ ml with IFN/HU and within the normal range with HU. This aim was achieved in the majority of cases. The IFN dose required to achieve this aim declined over the years in agreement with the low IFN doses required for remission maintenance in other studies. The dose was 20-25% lower with the IFN/HU combination therapy in CML-study II than with IFN monotherapy in CML-study I (about 2.4 vs 3 Mill IU/m 2 /day at 30 months and about 1.7 vs 2 Mill IU/m 2 /day at 60 months). 2, 27, 31 In contrast, the required HU doses remained rather constant over the years.
In summary, we conclude that the IFN/HU combination therapy is more effective than HU or IFN alone and, for the time being, with regard to the superior long-term survival, it should 
Figure 7
Duration of chronic phase in patients treated with IFN/ HU combination therapy (n ¼ 226) vs HU monotherapy (n ¼ 308). Interferon a and hydroxyurea vs hydroxyurea alone R Hehlmann et al be considered standard therapy of CML and used for comparisons with new drugs and treatment modalities.
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